Congress Wealth Management LLC DE Buys 151,796 Shares of DexCom, Inc. (NASDAQ:DXCM)

Congress Wealth Management LLC DE grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 865.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,338 shares of the medical device company's stock after buying an additional 151,796 shares during the quarter. Congress Wealth Management LLC DE's holdings in DexCom were worth $13,170,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Empowered Funds LLC raised its stake in DexCom by 6.1% during the 3rd quarter. Empowered Funds LLC now owns 5,847 shares of the medical device company's stock valued at $392,000 after purchasing an additional 335 shares during the period. Cerity Partners LLC lifted its stake in DexCom by 190.0% in the 3rd quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company's stock worth $4,026,000 after acquiring an additional 39,344 shares in the last quarter. Swedbank AB boosted its position in DexCom by 15.2% during the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company's stock worth $14,337,000 after acquiring an additional 28,289 shares during the period. Daiwa Securities Group Inc. grew its stake in DexCom by 0.6% during the 3rd quarter. Daiwa Securities Group Inc. now owns 77,099 shares of the medical device company's stock valued at $5,169,000 after acquiring an additional 490 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in shares of DexCom by 10.6% in the 3rd quarter. Fisher Asset Management LLC now owns 856,124 shares of the medical device company's stock valued at $57,395,000 after purchasing an additional 82,250 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Remove Ads

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

DXCM traded down $1.73 during trading on Friday, reaching $67.74. 4,680,803 shares of the company's stock were exchanged, compared to its average volume of 4,055,857. The company has a market capitalization of $26.47 billion, a P/E ratio of 47.37, a PEG ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a 50 day moving average price of $82.32 and a 200 day moving average price of $77.01. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $141.99.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on DXCM shares. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and increased their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and raised their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.